These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36002761)

  • 1. Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed.
    Citrome L; Risinger R; Rajachandran L; Robison H
    Adv Ther; 2022 Oct; 39(10):4821-4835. PubMed ID: 36002761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial.
    Preskorn SH; Zeller S; Citrome L; Finman J; Goldberg JF; Fava M; Kakar R; De Vivo M; Yocca FD; Risinger R
    JAMA; 2022 Feb; 327(8):727-736. PubMed ID: 35191924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial.
    Citrome L; Preskorn SH; Lauriello J; Krystal JH; Kakar R; Finman J; De Vivo M; Yocca FD; Risinger R; Rajachandran L
    J Clin Psychiatry; 2022 Oct; 83(6):. PubMed ID: 36198061
    [No Abstract]   [Full Text] [Related]  

  • 4. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2019 Oct; 73(10):e13397. PubMed ID: 31355510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sublingual dexmedetomidine: repurposing an anesthetic as an anti-agitation agent.
    Faden J; Musselman M; Citrome L
    Expert Rev Neurother; 2023 Feb; 23(2):97-106. PubMed ID: 36707066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Agitation in Individuals With Bipolar Disorder or Schizophrenia: Lessons Learned for Clinical Psychiatry and Psychiatric Drug Development.
    Preskorn SH
    J Psychiatr Pract; 2022 Jul; 28(4):319-323. PubMed ID: 35797688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction to: Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed.
    Citrome L; Risinger R; Rajachandran L; Robison H
    Adv Ther; 2023 Jan; 40(1):391. PubMed ID: 36315340
    [No Abstract]   [Full Text] [Related]  

  • 9. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Citrome L
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Ketter TA; Cucchiaro J; Loebel A
    J Affect Disord; 2014 Feb; 155():20-7. PubMed ID: 24246116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexmedetomidine Sublingual Film: A New Treatment to Reduce Agitation in Schizophrenia and Bipolar Disorders.
    Karlin DM; Nelson LA; Campbell AR
    Ann Pharmacother; 2024 Jan; 58(1):54-64. PubMed ID: 37119212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual Dexmedetomidine for the Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder.
    Smith CM; Santalucia M; Bunn H; Muzyk A
    Clin Psychopharmacol Neurosci; 2023 May; 21(2):215-221. PubMed ID: 37119214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lumateperone for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
    Citrome L; Durgam S; Edwards JB; Davis RE
    J Clin Psychiatry; 2023 Mar; 84(2):. PubMed ID: 36883881
    [No Abstract]   [Full Text] [Related]  

  • 14. Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder.
    Citrome L
    Int J Clin Pract; 2011 Mar; 65(3):330-40. PubMed ID: 21199198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.
    Gao K; Ganocy SJ; Gajwani P; Muzina DJ; Kemp DE; Calabrese JR
    J Clin Psychiatry; 2008 Feb; 69(2):302-9. PubMed ID: 18211129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
    Citrome L
    Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular aripiprazole in the control of agitation.
    Currier GW; Citrome LL; Zimbroff DL; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
    J Psychiatr Pract; 2007 May; 13(3):159-69. PubMed ID: 17522559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.
    Wang Z; Kemp DE; Chan PK; Fang Y; Ganocy SJ; Calabrese JR; Gao K
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):131-42. PubMed ID: 20875219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.